UA115078C2 - Спосіб центральної локорегіонарної анестезії фармацевтичним водним розчином хлоропрокаїну - Google Patents
Спосіб центральної локорегіонарної анестезії фармацевтичним водним розчином хлоропрокаїнуInfo
- Publication number
- UA115078C2 UA115078C2 UAA201506088A UAA201506088A UA115078C2 UA 115078 C2 UA115078 C2 UA 115078C2 UA A201506088 A UAA201506088 A UA A201506088A UA A201506088 A UAA201506088 A UA A201506088A UA 115078 C2 UA115078 C2 UA 115078C2
- Authority
- UA
- Ukraine
- Prior art keywords
- chloroprocaine
- intrathecal administration
- pharmaceutical composition
- based pharmaceutical
- repeated intrathecal
- Prior art date
Links
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002023 chloroprocaine Drugs 0.000 title abstract 3
- 238000007913 intrathecal administration Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 238000002694 regional anesthesia Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Винахід стосується способу центральної локорегіонарної анестезії, який включає повторюване інтратекальне введення ін'єкційного фармацевтичного водного розчину хлоропрокаїну або його солей, який не містить консервантів та/або антиоксиданта і який має рН від 3 до 4, причому хлоропрокаїн вводять у дозі, яка становить 15-80 мг на добу, і при цьому згадане інтратекальне введення повторюють протягом пepioду часу тpивaлістю від 2 до 10 днів.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002120A ITMI20122120A1 (it) | 2012-12-12 | 2012-12-12 | Composizione farmaceutica a base di cloroprocaina per la somministrazione intratecale ripetuta |
| PCT/IB2013/060801 WO2014091420A1 (en) | 2012-12-12 | 2013-12-11 | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA115078C2 true UA115078C2 (uk) | 2017-09-11 |
Family
ID=47633206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201506088A UA115078C2 (uk) | 2012-12-12 | 2013-12-11 | Спосіб центральної локорегіонарної анестезії фармацевтичним водним розчином хлоропрокаїну |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9504666B2 (uk) |
| KR (1) | KR102162587B1 (uk) |
| CN (1) | CN105283222A (uk) |
| AR (1) | AR099443A1 (uk) |
| AU (1) | AU2013356855B2 (uk) |
| IL (1) | IL239270B (uk) |
| IT (1) | ITMI20122120A1 (uk) |
| MX (1) | MX2015007288A (uk) |
| MY (1) | MY180957A (uk) |
| NZ (1) | NZ709631A (uk) |
| PH (1) | PH12015501313B1 (uk) |
| RU (1) | RU2648823C2 (uk) |
| SG (1) | SG11201504572WA (uk) |
| UA (1) | UA115078C2 (uk) |
| WO (1) | WO2014091420A1 (uk) |
| ZA (1) | ZA201504618B (uk) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20201281A1 (es) * | 2017-09-15 | 2020-11-24 | Sintetica S A | Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas |
| CN111494310A (zh) * | 2020-04-29 | 2020-08-07 | 周晓玲 | 一种局部麻醉药物的制备及使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003299885A1 (en) * | 2002-12-20 | 2004-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Ester combination local anesthetic |
| ITMI20051633A1 (it) * | 2005-09-06 | 2007-03-07 | Sint Sa | Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione |
-
2012
- 2012-12-12 IT IT002120A patent/ITMI20122120A1/it unknown
-
2013
- 2013-12-09 AR ARP130104578A patent/AR099443A1/es unknown
- 2013-12-11 UA UAA201506088A patent/UA115078C2/uk unknown
- 2013-12-11 AU AU2013356855A patent/AU2013356855B2/en active Active
- 2013-12-11 US US14/650,583 patent/US9504666B2/en active Active
- 2013-12-11 NZ NZ709631A patent/NZ709631A/en unknown
- 2013-12-11 MY MYPI2015701905A patent/MY180957A/en unknown
- 2013-12-11 MX MX2015007288A patent/MX2015007288A/es unknown
- 2013-12-11 WO PCT/IB2013/060801 patent/WO2014091420A1/en not_active Ceased
- 2013-12-11 SG SG11201504572WA patent/SG11201504572WA/en unknown
- 2013-12-11 KR KR1020157018300A patent/KR102162587B1/ko active Active
- 2013-12-11 CN CN201380065146.8A patent/CN105283222A/zh active Pending
- 2013-12-11 RU RU2015128024A patent/RU2648823C2/ru active
-
2015
- 2015-06-07 IL IL239270A patent/IL239270B/en active IP Right Grant
- 2015-06-09 PH PH12015501313A patent/PH12015501313B1/en unknown
- 2015-06-25 ZA ZA2015/04618A patent/ZA201504618B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015501313A1 (en) | 2015-08-24 |
| AU2013356855A1 (en) | 2015-07-23 |
| WO2014091420A1 (en) | 2014-06-19 |
| IL239270B (en) | 2018-03-29 |
| SG11201504572WA (en) | 2015-07-30 |
| KR102162587B1 (ko) | 2020-10-08 |
| IL239270A0 (en) | 2015-07-30 |
| KR20150085131A (ko) | 2015-07-22 |
| US20150320716A1 (en) | 2015-11-12 |
| PH12015501313B1 (en) | 2015-08-24 |
| AU2013356855B2 (en) | 2018-02-15 |
| ZA201504618B (en) | 2019-01-30 |
| ITMI20122120A1 (it) | 2014-06-13 |
| RU2648823C2 (ru) | 2018-03-28 |
| MY180957A (en) | 2020-12-14 |
| NZ709631A (en) | 2020-03-27 |
| AR099443A1 (es) | 2016-07-27 |
| MX2015007288A (es) | 2015-09-10 |
| US9504666B2 (en) | 2016-11-29 |
| CN105283222A (zh) | 2016-01-27 |
| RU2015128024A (ru) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| NZ709958A (en) | Enhanced stability of novel liquid compositions | |
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| PH12012502454A1 (en) | Formulations including amiodarone and salts thereof and methods of their manufacture and use | |
| MY174729A (en) | Pharmaceutical combination drug | |
| WO2014007770A3 (en) | Inhalation compositions comprising corticosteroid and sorbitol | |
| WO2014007772A3 (en) | Inhalation compositions comprising glucose anhydrous | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| WO2014007781A3 (en) | Inhalation compositions | |
| WO2014007771A3 (en) | Inhalation compositions comprising muscarinic receptor antagonist | |
| IN2015DN02999A (uk) | ||
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| PH12015501313B1 (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
| EP2682103A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol | |
| LV15003A (lv) | Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei | |
| MX355103B (es) | Composicion para el tratamiento de desordenes inflamatorios e inmunes. | |
| GR1008039B (el) | Σταθερο ενεσιμο φαρμακευτικο σκευασμα ενος αγωνιστη των υποδοχεων της βιταμινης d και μεθοδος για την παρασκευη αυτου | |
| MX2013003022A (es) | Composiciones farmaceuticas de montelukast y levocetirizina. | |
| UA85352U (uk) | Фармацевтичний продукт, що містить налбуфін |